Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies

BACKGROUND/AIM: Since the outbreak of the COVID-19, numerous therapies to counteract this severe disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored. MATERIALS AND METHODS: A systematic search adherin...

Descripción completa

Detalles Bibliográficos
Autores principales: SARFRAZ, Azza, SARFRAZ, Zouina, SARFRAZ, Muzna, AFTAB, Hinna, PERVAIZ, Zainab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283492/
https://www.ncbi.nlm.nih.gov/pubmed/33244947
http://dx.doi.org/10.3906/sag-2010-131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283492/
https://www.ncbi.nlm.nih.gov/pubmed/33244947
http://dx.doi.org/10.3906/sag-2010-131

Ejemplares similares